… This grant builds upon the research from a prior grant: Uric Acid as an Antioxidant Treatment … in the LRRK2 gene. Project Description: Blood samples from people with LRRK2-associated PD, people without PD but … capacity. If those are elevated in blood samples from people with LRRK2-associated Parkinson's, we will …

… has yet to be defined. Many investigators feel that damage from free radical play an important role in the disease … anti-oxidant therapy has so provided disappointing results from a clinical standpoint. In this project we will explore … of protection around the mitochondria, to protect it from oxidative damage. We will use two strategies for …

… inflammatory molecules, called proinflammatory cytokines, from glial cells in the brain can contribute to nerve cell … Minokine confers a protective effect onto dopamine neurons from MPTP-induced injury by an unknown cellular mechanism. … an inhibitor of MAO-A, MAO-B or CYP2D6. We cannot conclude from the feasibility study whether or not Minokine had an in …

… have been pursuing ghrelin as a therapeutic target from the perspective of metabolic disorders. Currently, … numerous ghrelin-like compounds have been emerging from human trials. Thus, there will be a rapid translation … of the brain's dopamine cells. Because ghrelin originates from the stomach, it is circulating normally in the body, so …

… (NGRC) and recruited over 4,000 PD patients and controls from four U.S. investigator sites. Initially, as set by the … Genetics. Additionally, follow-on funding has been obtained from the National Institute of Neurological Disorders and … Veterans Affairs. Additional follow-on funding is pending from NINDS. …

… marker GFAP (glial fibrillary acidic protein) in biopsies from PD patients and healthy controls. In a second set of … the fact that the core pathology lies in the brain, hidden from direct study in living patients. The recent … phosphate group was significantly lower in GFAP extracted from gut biopsies of PD patients as compared to healthy …